Sponsor: COG
Sponsor Study ID: AALL1621
Study Title: A Phase 2 Study of Inotuzumab Ozogamicin (NSC# 772518) in Children and Young Adults With Relapsed or Refractory CD22+ B Acute Lymphoblastic Leukemia (B ALL)
CTO #: 103488
NCT Number: NCT02981628
Phase: II
Protocol Type: Treatment
Age Group: Both
Disease Sites: Lymphoid Leukemia
Study Objectives: This phase II trial studies how well inotuzumab ozogamicin works in treating younger patients with B-lymphoblastic lymphoma or CD22 positive B acute lymphoblastic leukemia that has come back (relapsed) or does not respond to treatment (refractory). Inotuzumab ozogamicin is a monoclonal antibody, called inotuzumab, linked to a toxic agent called ozogamicin. Inotuzumab attaches to CD22 positive cancer cells in a targeted way and delivers ozogamicin to kill them.